WuXi AppTec Corporate Ventures

WuXi AppTec Corporate Ventures is the corporate venture capital arm of WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device company headquartered in Shanghai, China. The firm focuses on investing in innovative healthcare and life science companies to advance drug discovery and development. WuXi AppTec operates across Asia, Europe, and North America, offering integrated, end-to-end services through its unique Contract Research, Development, and Manufacturing Organization (CRDMO) platform. This platform enables the company to collaborate with nearly 6,000 partners across more than 30 countries, supporting their efforts to bring breakthrough treatments to patients. Guided by the vision that every drug can be made and every disease can be treated, WuXi AppTec is committed to advancing breakthroughs for patients—one collaboration at a time.

The investment strategy of WuXi AppTec Corporate Ventures encompasses various stages of company development, including seed, early stage, growth, and late stage. The firm has a broad geographical focus, with investments spanning China, the United States, Germany, Switzerland, and Singapore. Its industry focus includes healthcare, biotechnology, pharmaceuticals, medical devices, and life sciences. While specific investment sizes are not publicly disclosed, the firm's extensive network and resources position it to make significant contributions to the growth and success of its portfolio companies.

WuXi AppTec's track record reflects a strong commitment to innovation and collaboration in the healthcare and life sciences sectors. The company's integrated services and global presence enable it to identify and support promising companies that align with its mission to advance drug discovery and development. Through strategic investments and partnerships, WuXi AppTec Corporate Ventures plays a pivotal role in fostering innovation and delivering impactful solutions to the healthcare industry.